drugset / Trial / NCT00442897
Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)
RandomizedParallel-groupOpen-labelTreatment
Summary
Evaluate the proportion of hyperlipaemic persons with known coronary heart disease achieving ldl-c goal as defined by the national cholesterol education program (NCEP) adult treatment panel (ATP) III guidelines
Timeline
- Start
- 2006-09
- Primary completion
- 2008-10
- Completion
- 2008-10
Outcome
Met primary endpoint
registry analysis (unspecified test); Vytorin vs Atorvastatin; Odds Ratio (OR) 3.714 (95% CI 1.77 to 7.78) NCT00442897 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Atorvastatin | Small molecule | 10 mg | Oral |
| Subject | Ezetimibe | Unknown | 20 mg | Oral |
| Subject | Simvastatin | Small molecule | 10 mg | Oral |